Attralus
- Company typePrivate
- Founded2020
- HeadquartersSan Francisco, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
Attralus firmographics
Firmographics- Name
- Attralus
- Legal name
- Attralus, Inc.
- Website
- https://attralus.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Attralus industry classification
Industry- Product category
- Amyloidosis Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- akta.pro primary industry
- Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)
Keywords
Where Attralus is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Attralus business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Therapeutic Product Sales: Pre-revenue clinical-stage biopharmaceutical company. Revenue expected from commercialization of pan-amyloid removal therapeutics (AT-02 and next-generation candidates) following regulatory approval. AT-02 is in Phase 1/2 trials with Phase 2 open-label extension ongoing.
- Diagnostic Imaging Agent Licensing: Bayer acquired global rights to AT-01 (124I-evuzamitide) and AT-05 (99mTc-p5+14) imaging agents in January 2026. Financial terms not disclosed. Attralus retains focus on therapeutic development.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Attralus product offering
Product offeringCore offering
Attralus is a clinical-stage biopharmaceutical company developing pan-amyloid removal (PAR) therapeutics that directly bind to and remove toxic amyloid deposits from organs and tissues in patients with systemic amyloidosis. Its lead candidate, AT-02 (zamubafusp alfa), is an IgG1 Fc-fusion biologic in Phase 2 development for AL amyloidosis. Following Bayer's January 2026 acquisition of its diagnostic imaging agents (AT-01 and AT-05), Attralus now focuses exclusively on advancing its therapeutic pipeline.
Differentiator
Problem solved
Functional benefit
Products and services
- AT-02 (zamubafusp alfa) AT-02 is Attralus's lead pan-amyloid removal (PAR) therapeutic — a novel IgG1 Fc-fusion biologic combining a proprietary amyloid-binding peptide with an IgG1 Fc region to target and remove toxic amyloid deposits. It is being developed for patients with AL amyloidosis and ATTR amyloidosis and is currently in a Phase 2 open-label extension study following completion of Phase 1. The FDA has granted Orphan Drug Designation for both AL and ATTR amyloidosis indications.
Quantifiable outcome
- AT-02 treatment showed mean eGFR increase of ~16 mL/min at Week 40 in AL amyloidosis patients in hematologic remission
- +3 more outcomes
Companies that use Attralus
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
Attralus technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Attralus partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- BayercoreBayer acquired global rights to AT-01 (124I-evuzamitide) and AT-05 (99mTc-p5+14) pan-amyloid radiotracer imaging agents from Attralus. AT-01 is in Phase 3 for cardiac amyloidosis diagnosis with FDA Breakthrough Therapy Designation. AT-05 is in Phase 1. Bayer will advance development and commercialization of diagnostic imaging agents. Financial terms not disclosed.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Attralus competitors and assessment
Company assessmentMarket position
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Attralus social profiles
Digital presenceAttralus financial estimates
Financial estimateRevenue estimate
Valuation estimate
Attralus leadership team
Management profileNumber of profiles
Profiles9 records
Attralus funding detail
Funding detailFunding overview
Funding rounds3 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Attralus M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Attralus
What does Attralus do?
Attralus is a clinical-stage biopharmaceutical company developing pan-amyloid removal (PAR) therapeutics that directly bind to and remove toxic amyloid deposits from organs and tissues in patients with systemic amyloidosis. Its lead candidate, AT-02 (zamubafusp alfa), is an IgG1 Fc-fusion biologic in Phase 2 development for AL amyloidosis. Following Bayer's January 2026 acquisition of its diagnostic imaging agents (AT-01 and AT-05), Attralus now focuses exclusively on advancing its therapeutic pipeline.
Is Attralus a public or private company?
Attralus is a private company. It is classified as venture growth investor backed and is currently operating.
When was Attralus founded?
Attralus was founded in 2020. It employs 11 to 50 people.
Where is Attralus based?
Attralus is headquartered in San Francisco, United States, in the North America region.
How does Attralus make money?
Two revenue lines are on record. Therapeutic Product Sales are the primary driver. The others are diagnostic Imaging Agent Licensing.
Does Attralus have an API?
No public API is recorded for Attralus.
What industry is Attralus in?
Attralus's product category is Amyloidosis Therapeutics. Its primary akta.pro industry code is HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds). Its NAICS code is 541714.